# NEU-002

Source: https://onco.cc/drugs/neu-002/  
OnCo record `neu-002` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

NEU-002 is an experimental enzyme therapy: elastase for intravenous delivery from Onchilles Pharma, in preclinical development for solid tumours.

## Summary

NEU-002 is an enzyme therapy: elastase for intravenous delivery from Onchilles Pharma. The intravenous counterpart of N17350, built on the same ELANE-pathway approach and designed to eliminate tumours while mobilising an adaptive immune response. Its furthest stage is preclinical development, for solid tumours (not specified). No clinical trial naming it is registered on ClinicalTrials.gov. Company: 'continues through preclinical development'. No registered trial. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Tags: pipeline
- Code: NEU-002
- Modality: Enzyme therapy: elastase for intravenous delivery
- Mechanism: The intravenous counterpart of N17350, built on the same ELANE-pathway approach and designed to eliminate tumours while mobilising an adaptive immune response.

## Sources

- Onchilles Pharma: onchillespharma.com: https://www.onchillespharma.com/
- Onchilles Pharma: onchillespharma.com: https://www.onchillespharma.com/

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Onchilles Pharma](https://onco.cc/companies/onchilles-pharma/)

---
JSON: https://onco.cc/api/v1/entities/neu-002.json